Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.45 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679600 | 1.00 | EPHX2 (0.60) | EPHX2KMT2AENPP2ITGB3ITGAV | |
| SCHEMBL8366872 | 0.88 | EPHX2 (0.75) | EPHX2KMT2ACASP3FABP7FABP5 | |
| SCHEMBL13852689 | 0.88 | EPHX2 (0.58) | EPHX2KMT2AITGB3ITGAVCASP3 | |
| SCHEMBL2465503 | 0.87 | EPHX2 (0.63) | EPHX2KMT2AITGB3ITGAVCASP3 | |
| SCHEMBL7103741 | 0.86 | EPHX2 (0.70) | EPHX2KMT2AENPP2CASP3NR1H4 | |
| SCHEMBL23212115 | 0.86 | EPHX2 (0.65) | EPHX2KMT2AITGB3ITGAVCASP3 | |
| SCHEMBL2465375 | 0.86 | EPHX2 (0.62) | EPHX2KMT2AITGB3ITGAVCASP3 | |
| SCHEMBL15160758 | 0.86 | EPHX2 (0.62) | EPHX2KMT2ACASP3FABP7FABP5 | |
| SCHEMBL31607197 | 0.86 | EPHX2 (0.65) | EPHX2KMT2AITGB3ITGAVCASP3 | |
| SCHEMBL5931063 | 0.85 | KMT2A (0.61) | EPHX2KMT2AITGB3ITGAVCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263238-A1 | NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF | IMMUNOGEN, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160263238-A1 | NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF | IMMUNOGEN, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9289512-B2 | Maytansinoid derivatives with peptide linker and conjugates thereof | IMMUNOGEN, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289512-B2 | Maytansinoid derivatives with peptide linker and conjugates thereof | IMMUNOGEN, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2723389-A2 | NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF | Immunogen, Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| CN-103648532-A | Novel maytansinoid derivatives with peptide linker and conjugates thereof | IMMUNOGEN INC | 2014-03-19 | — | — | CN | disclosed |
| US-20130136691-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2013-05-30 | — | — | US | disclosed |
| US-8444954-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2013-05-21 | — | — | US | disclosed |
| US-8420053-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2013-04-16 | — | — | US | disclosed |
| US-8420050-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2013-04-16 | — | — | US | disclosed |
| WO-1999025685-A1 | 4-SUBSTITUTED-4-PIPERIDINE CARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0914333-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-12 | — | — | EP | disclosed |
| CN-1213379-A | Peptide derivatives | ZENECA LTD (GB) | 1999-04-07 | — | — | CN | disclosed |
| EP-0882066-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998042656-A1 | NOVEL COMPOUNDS | CYTEL CORPORATION (US) | 1998-10-01 | — | — | WO | disclosed |
| WO-1998025951-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998023644-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-06-04 | — | — | WO | disclosed |
| WO-1998017680-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | ZENECA LIMITED (GB) | 1998-04-30 | — | — | WO | disclosed |
| WO-1997046578-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997031023-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136691-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | GRPR, GIPR, GHRHR | EPHX2 4140/4885KMT2A 4582/4885ENPP2 136/4885 |
| US-20160263238-A1 | NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF | VIP, HDGF, NGLY1 | EPHX2 1845/4885KMT2A 3960/4885ENPP2 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.